Abstract:Genetic testing has been applied for decades in clinical routine diagnostics of hematological malignancies to improve disease (sub)classification, prognostication, patient management and survival. In recent classifications of hematological malignancies, disease subtypes are defined by key recurrent genetic alterations detected by conventional methods (i.e., cytogenetics, FISH, and targeted sequencing). Hematological malignancies were also one of the first disease areas in which targeted therapies were introduced, the prime example being BCR::ABL1 inhibitors, followed by an increasing number of targeted inhibitors hitting the Achilles' heel of each disease, resulting in a clear patient benefit. Owing to the technical advances in high‐throughput sequencing, we can now apply broad genomic tests, including comprehensive gene panels or whole‐genome and whole‐transcriptome sequencing, to identify clinically important diagnostic, prognostic and predictive markers. In this review, we give examples of how precision diagnostics have been implemented to guide treatment selection and improve survival in myeloid (myelodysplastic syndrome, acute myeloid leukemia) and lymphoid malignancies (acute lymphoblastic leukemia, diffuse large B cell lymphoma, chronic lymphocytic leukemia). We discuss the relevance and potential of monitoring measurable residual disease using ultra‐sensitive techniques to assess therapy response and detect early relapses. Finally, we bring up the promising avenue of functional precision medicine, combining ex vivo drug screening with various omics technologies, to provide novel treatment options for patients with advanced disease. Although we are only in the beginning of the field of precision hematology, we foresee rapid development with new types of diagnostics and treatment strategies becoming available to the benefit of our patients. This article is protected by copyright. All rights reserved

Precision diagnosis and treatment for hematological tumors

Precision diagnosis and treatment for hematological malignancies

Novel precision medicine approaches and treatment strategies in hematological malignancies

[Advances in the Target Therapy of Hematological Malignancies].

Advances and Prospect of Hematology

Development and Application of Nanomaterials, Nanotechnology and Nanomedicine for Treating Hematological Malignancies

Precision Diagnosis and Treatment of Liver Cancer in China.

Targeted single‐cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis‐resistant state in hematologic malignancies

The advanced development of molecular targeted therapy for hepatocellular carcinoma

Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies

Research Advances in Molecular Classification for Precision Diagnosis and Treatment of Hepatocellular Carcinoma

Epigenetic Regulation in Hematopoiesis and Its Implications in the Targeted Therapy of Hematologic Malignancies

Application of Multidisciplinary Team in Precision Oncology and Immunotherapy for Hepatobiliary Malignancies

Overview of molecular diagnosis and targeted treatment of tumor

The Essential Roles of Small Non-Coding RNAs and RNA Modifications in Normal and Malignant Hematopoiesis

The Progress of Epigenetic Modification in Hematological Malignancies Research

Single‐Cell RNA Sequencing in Hematological Diseases

Application of high-throughput gene sequencing in lymphoma

Recent Progress of Exosomes in Hematological Malignancies: Pathogenesis, Diagnosis, and Therapeutic Strategies

Immunotherapy in hematologic malignancies: achievements, challenges and future prospects

Diagnosis and Treatment of Breast Cancer in the Precision Medicine Era